Barclays lifted its price target on Johnson & Johnson (NYSE:JNJ) to $197 from $176 on December 2 while maintaining an ...
Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim ...
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...
The FDA’s Circulatory System Devices Panel voted not to recommend approving use of an interatrial shunt to improve heart failure symptoms and prognosis.In a 0-15 vote, the committee determined risk ...
Bristol Myers Squibb has struggled over the past few years due to patent cliffs. And to make matters worse, it will soon face ...
WASHINGTON, Dec. 4, 2025 /PRNewswire/ — The Association of Black Cardiologists (ABC) proudly announces the recipients of its ...
Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...
Taylor Brooks has just announced that Perk Imaging has signed a lease for Shevlin Crossing Building B, introducing an ...
Co-led by SemperVirens Venture Capital and Next Ventures, with participation by Sanofi Ventures, Lux Capital, Civilization ...
A new study conducted across three African countries has found that an injectable HIV treatment--Cabotegravir/Rilpivirine (CAB LA + RPV LA), administered every two months--is safe, well tolerated, and ...
University of Arkansas System President Jay B. Silveria has named four finalists to be the next University of Arkansas for ...
RWJUH and Rutgers RWJMS designated a National Rare Disease Center of Excellence from NORD, highlighting leadership in rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback